Skip to content
DataLookout
Menu

NCT07739901

Korean Real-world Study on MASLD/MASH Outcomes.

StatusActive, Not Recruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved at least 2 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 11 words
    • Primary and study completion pushed from Sep 30, 2026 to Dec 28, 2026
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Occurrence of decompensated cirrhosis
Timeframe: From index date (second VCTE and start of follow-up) to the first occurrence of major adverse liver outcome (MALO) (up to 31 Dec 2025)
Occurrence of hepatocellular carcinoma (HCC) confirmed by imaging or biopsy
Timeframe: From index date (second VCTE and start of follow-up) to the first occurrence of MALO (up to 31 Dec 2025)
Liver transplantation
Timeframe: From index date (second VCTE and start of follow-up) to the first occurrence of MALO (up to 31 Dec 2025)
All-cause death
Timeframe: From index date (second VCTE and start of follow-up) to the first occurrence of MALO (up to 31 Dec 2025)

Arms and interventions

cohort with MASLD/MASH

Adults with MASLD/MASH who had at least two VCTE-LSM assessments performed 1 to 5 years apart during routine clinical care. Medical records will be reviewed to assess the association between changes in VCTE-LSM risk tier and long-term clinical outcomes.

Other: No treatment is given

Sites

1 site in 1 country

  • Novo Nordisk Investigational SiteSeoul, South Korea